Prenetics Taps Consumer Health CFO to Scale IM8’s Rapid Global Expansion — Prenetics Global Limited

Event summary

Prenetics appoints Brian J. Rosin as U.S. Chief Financial Officer of IM8, effective May 14, 2026.
Rosin brings nearly two decades of experience in consumer e-Commerce and premium wellness subscription brands.
IM8 projects $190 million to $210 million in revenue for 2026, its second year of operations.
IM8 is sold in more than 40 countries and has surpassed $100 million in annualized recurring revenue within 11 months of launch.

The big picture

Prenetics' appointment of Brian J. Rosin as CFO of IM8 underscores the company's focus on scaling its premium health and longevity brand globally. Rosin's extensive experience in consumer health and e-Commerce positions IM8 to navigate the complexities of rapid expansion while maintaining strong unit economics. The move comes as IM8 aims to solidify its position as a leader in the premium daily nutrition category, leveraging high-profile partnerships and science-backed formulations to drive growth.

What we're watching

Scaling Challenges: How IM8 will maintain its rapid growth pace while ensuring financial discipline and infrastructure support its global expansion.
Market Leadership: Whether IM8 can sustain its category leadership in premium daily nutrition amid increasing competition.
Financial Performance: The pace at which IM8 can achieve profitability as it scales operations across more than 40 countries.